Back to Journals Drug Design, Development and Therapy Volume 20 GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation Received 1 April 2026 Accepted for publication 2 June 2026 Published 12 June 2026 Volume 2026:20 613616 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Editor who approved publication: Professor Anastasios Lymperopoulos Pengpeng Li, Yangyang Gao, Wei Liu Department of Neurosurgery, Xian Aerospace Hospital of Northwest University, Xian, Shanxi, 710000, Peoples Republic of China Correspondence: Pengpeng Li, Email [email protected] Wei Liu, Email [email protected] Abstract: Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, have been used for years to treat type 2 diabetes and obesity
Zepbound (tirzepatide) is an FDA-approved medication for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
GLP-1 Weight Loss Medications Support appetite control and weight management as part of medically supervised weight loss programs
FRANKFORT During another jam-packed week in the 2026 legislative session, lawmakers advanced two bills on child care, gave a nod to first responders and sparred twice over a proposal to allow conscientious objections for health care workers in Kentucky
